Potassium channel modulators and schizophrenia: an overview of investigational drugs.

Musselman, Meghan; Huynh, Eric; Kelshikar, Rachana; Lee, Eric; Malik, Mohammed; Faden, Justin

Musselman, Meghan; Huynh, Eric; Kelshikar, Rachana; Lee, Eric; Malik, Mohammed; Faden, Justin.

Afiliação

Musselman M; Department of Psychiatry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Huynh E; Department of Psychiatry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Kelshikar R; Department of Psychiatry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Lee E; Department of Psychiatry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Malik M; Department of Psychiatry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Faden J; Department of Psychiatry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.

Expert Opin Investig Drugs ; 32(6): 471-477, 2023.

Article em En | MEDLINE | ID: mdl-37247333

Assuntos

Canais de Potássio; Esquizofrenia; Humanos; Canais de Potássio/fisiologia; Drogas em Investigação/farmacologia; Drogas em Investigação/uso terapêutico; Esquizofrenia/tratamento farmacológico; Ácido gama-Aminobutírico; Receptores Dopaminérgicos

Palavras-chave

AUT00206; NMDA receptor; Schizophrenia; gamma oscillations; glutamate; potassium channel modulators; psychopharmacology

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Canais de Potássio Limite: Humans Idioma: En Revista: Expert Opin Investig Drugs Assunto da revista: TERAPIA POR MEDICAMENTOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google